ChromaDex (NASDAQ:CDXC) COO Robert N. Fried bought 10,000 shares of the firm’s stock in a transaction on Tuesday, May 15th. The stock was purchased at an average price of $3.63 per share, with a total value of $36,300.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
NASDAQ CDXC traded down $0.10 on Thursday, hitting $3.51. The stock had a trading volume of 287,300 shares, compared to its average volume of 421,179. ChromaDex has a one year low of $3.60 and a one year high of $3.73. The company has a current ratio of 5.22, a quick ratio of 4.71 and a debt-to-equity ratio of 0.01. The stock has a market cap of $198.07 million, a price-to-earnings ratio of -10.60 and a beta of 1.08.
ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings data on Thursday, May 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.09). The company had revenue of $6.57 million during the quarter, compared to the consensus estimate of $6.50 million. ChromaDex had a negative net margin of 70.19% and a negative return on equity of 56.28%. equities research analysts expect that ChromaDex will post -0.34 earnings per share for the current fiscal year.
Several research analysts have commented on CDXC shares. HC Wainwright set a $8.00 target price on shares of ChromaDex and gave the stock a “buy” rating in a research report on Tuesday, January 23rd. BidaskClub cut shares of ChromaDex from a “hold” rating to a “sell” rating in a research report on Friday, January 26th. ValuEngine upgraded shares of ChromaDex from a “sell” rating to a “hold” rating in a research report on Thursday, February 8th. Finally, Zacks Investment Research cut shares of ChromaDex from a “hold” rating to a “sell” rating in a research report on Monday, February 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $7.50.
Several institutional investors have recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in shares of ChromaDex by 61.1% in the fourth quarter. Millennium Management LLC now owns 542,994 shares of the company’s stock valued at $3,193,000 after acquiring an additional 205,852 shares in the last quarter. UBS Group AG boosted its holdings in shares of ChromaDex by 94.1% in the first quarter. UBS Group AG now owns 121,412 shares of the company’s stock valued at $510,000 after acquiring an additional 58,848 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of ChromaDex by 9.8% in the fourth quarter. BlackRock Inc. now owns 111,207 shares of the company’s stock valued at $654,000 after acquiring an additional 9,917 shares in the last quarter. Oppenheimer & Co. Inc. boosted its holdings in shares of ChromaDex by 117.6% in the first quarter. Oppenheimer & Co. Inc. now owns 92,500 shares of the company’s stock valued at $389,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Tibra Equities Europe Ltd bought a new position in shares of ChromaDex in the first quarter valued at approximately $320,000. Institutional investors and hedge funds own 9.82% of the company’s stock.
ChromaDex Company Profile
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.